x
Filter:
Filters applied
- JAH_Position_Papers
- Rapid CommunicationRemove Rapid Communication filter
- EditorialRemove Editorial filter
- Rosenthal, Susan LRemove Rosenthal, Susan L filter
SAHM Position & Statement Papers
2 Results
- Position statement
Human Papillomavirus (HPV) Vaccine: A Position Statement of the Society for Adolescent Medicine
Journal of Adolescent HealthVol. 39Issue 4p620Published in issue: October, 2006- Lawrence S. Friedman
- Jessica Kahn
- Amy B. Middleman
- Susan L. Rosenthal
- Gregory D. Zimet
Cited in Scopus: 23Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide, causing genital warts and nearly all cases of cervical cancer. On June 8, 2006, the Food and Drug Administration approved a three-dose HPV vaccine for use in females 9 to 26 years of age. The vaccine has been shown to be safe and effective in preventing infection with HPV types 16 and 18 (which cause approximately 70% of cervical cancers) as well as types 6 and 11 (which cause >90% of genital warts). As a prophylactic vaccine, it is most effective when administered before the onset of sexual activity. - Position statement
Meningococcal vaccine: Position statement of the Society for Adolescent Medicine
Journal of Adolescent HealthVol. 37Issue 3p262Published in issue: September, 2005- Amy B. Middleman
- Vaughn I. Rickert
- Susan L. Rosenthal
Cited in Scopus: 1The incidence of meningococcal disease peaks during the neonatal years and again during the adolescent years. Most adolescent cases are vaccine preventable using the current tetravalent meningococcal vaccines. In February 2005, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention recommended routine immunization with the tetravalent conjugate meningococcal vaccine of all 11–12-year-olds, with the interim recommendation including all 14–15-year-olds, and special targeted populations to include incoming college freshmen living in dormitories, military recruits, certain travelers, microbiologists working with Neisseria meningitidis, and those with terminal complement component deficiencies and asplenia.
